1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-SC0136 |
Product Category | Stem Cells |
Size/Quantity | 1 vial |
Cell Type | Stem Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Breast |
Disease | Breast Cancer |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Human Cancer Stem Cells |
Human Parental Breast Cancer Stem Cells are mainly derived from breast cancer tissues. These cells have the potential for self-renewal and multidirectional differentiation, and are considered to be key drivers of tumorigenesis, metastasis, drug resistance and recurrence. Morphologically, they are often round or oval, relatively small in size, with a high nuclear-to-cytoplasmic ratio and prominent nucleoli. Karyotype analysis often reveals chromosomal instability. Common mutations include TP53, PIK3CA, and BRCA1/2. They express stemness markers such as Oct-4 and Nanog. They can differentiate into luminal epithelial and myoepithelial cells. These cells are particularly relevant in triple-negative breast cancer models, ideal for studying tumorigenesis and therapy resistance.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human breast cancer stem cells have critical applications in advancing our understanding and treatment of breast cancer. By being able to identify these tumorigenic cancer cells, researchers can explore the pathways that regulate their growth and survival, offering valuable insights into breast cancer biology. Moreover, since these cells are responsible for driving tumor development, targeting this specific population can lead to more effective therapies. The validation of cancer cell lines as models for studying the unique mechanisms of maintenance and survival in breast cancer stem cells also supports the development of new therapies targeting these cells and improve patient outcomes.